CCO HIV Stay Tuned 

Bimonthly CME-certified audio Podcasts, each supported by a variety of online resources.

Integrating HIV Therapeutic Advances Into Clinical Practice—Volume 3, Edition 1 In this edition of Stay Tuned, Eric S. Daar, MD, discusses data presented at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy on new agents for HIV in the development pipeline; Kathleen E. Squires, MD, provides insight into the management of HIV-infected pregnant women; Kimberly Y. Smith, MD, MPH, discusses the lower response rates to antiretroviral therapy among black patients and strategies to address this issue; Douglas Ward, MD, discusses emerging data on drug interactions between antiretrovirals, tobacco, and recreational drugs; and Robert W. Coombs, MD, PhD, FRCPC, discusses newer HIV-1 RNA tests and provides insight into the clinical implications of more precise HIV-1 RNA monitoring. Audio, video, Capsule Summaries, and slideset downloads are also provided for additional reference. Click here to start.

Answering the Questions: Clinical Considerations in the Use of Integrase Inhibitors

CCO’s expert faculty members provide answers to frequently asked questions about key clinical considerations when incorporating HIV integrase inhibitors into an antiretroviral regimen.

Now Available!

CME-Certified Modules:

Answering the Questions: Clinical Considerations in the Use of Integrase Inhibitors William G. Powderly, MD; Paul E. Sax, MD; and Jonathan M. Schapiro, MD, address pressing questions regarding the use of HIV integrase inhibitors in clinical practice. Faculty Responses to Additional Questions on the Use of Integrase Inhibitors in Clinical Practice William G. Powderly, MD; Paul E. Sax, MD; and Jonathan M. Schapiro, MD, answer the most compelling questions posed by readers on the use of integrase inhibitors in clinical practice.

Downloadable CCO Slideset:

Answering the Questions: Clinical Considerations in the Use of Integrase Inhibitors In this downloadable slideset, Jonathan M. Schapiro, MD, presents data on the most pressing questions regarding the use of HIV integrase inhibitors in clinical practice.

2009 Interscience Conference on Antimicrobial Agents and Chemotherapy 

CCO's official coverage of ICAAC 2009 includes Capsule Summaries of key presentations as well as an Expert Analysis and audio Expert Highlights that focus on key issues highlighted at the conference.

From Podium to Practice: HIV Highlights From San Francisco 
Judith S. Currier, MD, MSc; Joel E. Gallant, MD, MPH; and Kathleen E. Squires, MD

Now Available!

CME-Certified Expert Analysis:

CCO HIV Stay Tuned

Bimonthly CME-certified audio Podcasts, each supported by a variety of online resources.

Evolving Concepts in Antiretroviral Therapy—Volume 2, Edition 3 In this edition of Stay Tuned, David A. Wohl, MD, provides an update on the controversial relationship among abacavir use and increased risk of cardiovascular disease; Charles B. Hicks, MD, discusses recent data on a new integrase inhibitor and novel PI-based treatment strategies; C. Bradley Hare, MD, explores the clinical impact of the recent approval of raltegravir for use in first-line therapy; David M. Margolis, MD, provides an overview of the potential long-term consequences of acute HIV infection and chronic inflammation; and Andrew R. Zolopa, MD, discusses data on clinically relevant thresholds for minority antiretroviral-resistant viral populations. Audio, video, and slideset downloads are also provided for additional reference. Click here to start.

Class in Session: Defining the Role of the Newest Class of Antiretrovirals

This new treatment update delivers an in-depth analysis of the latest antiretroviral drug class, the integrase strand transfer inhibitors. CCO’s expert faculty members review the mechanism of action of these agents, the most recent clinical trial data on their safety and efficacy, and key management strategies for their optimal use in clinical practice.

Now Available!

CME-Certified Video Module:

Downloadable CCO Slidesets:

Weighing the Options: Choosing the Initial Antiretroviral Regimen

In this new treatment update, CCO’s expert faculty members review key considerations relevant to selecting an optimal first-line regimen for the treatment of HIV-infected patients. Topics include an analysis of comparative studies investigating antiretroviral regimens in the first-line setting, current consensus guideline recommendations, and individual patient characteristics that should be considered when choosing an initial regimen.

Now Available!

CME/CE-Certified Modules:

CME/CE-Certified Interactive Virtual Presentation:

Downloadable CCO Slideset:

CCO HIV Stay Tuned

Bimonthly CME-certified audio Podcasts, each supported by a variety of online resources.

Evolving Concepts in Antiretroviral Therapy—Volume 2, Edition 2 Watch and listen as Francesca T. Aweeka, PharmD, and Andrew R. Zolopa, MD, provide a pharmacologist’s and a clinician’s perspective on the potential interaction between etravirine and raltegravir; Kimberly Y. Smith, MD, MPH, explains how recently published data from the NA-ACCORD may affect clinical practice; Robert M. Grant, MD, MPH, describes a prevention strategy that involves use of antiretroviral agents to block transmission of HIV-1; Robert F. Siliciano, MD, PhD, discusses his research on the inhibitory potential of antiretroviral drugs with Andrew R. Zolopa, MD; and Lisa Capaldini, MD, shares her approach to determining when to initiate antiretroviral therapy in her patients. Then download audio, video, slidesets, Capsule Summaries, and Expert Viewpoints for additional references. Click here to start.

2009 IAS Conference on HIV Pathogenesis, Treatment and Prevention

CCO's official coverage of the 2009 IAS meeting includes Capsule Summaries of key presentations, as well as Expert Analyses, Slides, and audio Expert Highlights that focus on key issues highlighted at the conference. 

HIV Management in Developed Countries
Andrew Carr, MBBS, MD, FRACP, FRCP; Anton L. Pozniak, MD, FRCP; and Kimberly Y. Smith, MD, MPH 

HIV Management in Resource-Constrained Settings
James Hakim, MD; Elly Katabira, MD; Mauro Schechter, MD, PhD

Biomedical HIV Prevention Strategies
Sharon L. Hillier, PhD; Julio Montaner, MD, FRCPC, FCCP; Thomas Quinn, MD, MSc

Now Available!

CME-Certified Expert Analyses:

From Podium to Practice: HIV Management in Developed Countries Andrew Carr, MBBS, MD, FRACP, FRCP; Anton L. Pozniak, MD, FRCP; and Kimberly Y. Smith, MD, MPH, discuss key studies pertaining to the management of HIV infection in developed nations presented at the 2009 International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention with a focus on the implications of those findings for clinical practice.

HIV Management in Resource-Constrained Settings: the DART Trial In this Expert Analysis panel discussion, James G. Hakim, MBChB, MMed, MSc, FRCP; International AIDS Society President-Elect Elly Katabira, MD; and Mauro Schechter, MD, PhD, review results of the DART trial that were presented at the 2009 International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.

Biomedical HIV Prevention Strategies In this Expert Analysis on the 2009 IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sharon L. Hillier, PhD; Julio Montaner, MD, FRCPC, FCCP; and Thomas Quinn, MD, MSc, provide insight on several reports of prevention strategies and review the challenges and successes of these strategies.

HIV Journal Options - Volume 5, Issue 2

Stay up to date with the current HIV/AIDS literature through a CME-certified learning module with Expert Commentaries, Capsule Summaries, and CCO’s downloadable slidesets.

Topics include:

• Pretreatment CD4+ Cell Count and Recovery of T-Cell Subsets
• Incidence of Non-AIDS–Defining Cancers in HIV-Infected Patients
• Atazanavir/Ritonavir Monotherapy in Virologically Suppressed Patients
• CHER: Investigation of Antiretroviral Timing in HIV-Infected Infants
• Once- vs Twice-Daily Lopinavir/Ritonavir in Treatment-Naive Patients
• Initiating HAART in HIV/TB-Coinfected Patients
• Increased Mortality Among HIV-Infected Racial Minorities and Women
• Viability of Less Frequent Follow-ups in Virologically Suppressed Patients
  

Strategies for Success in the Most Complex Cases: A Master Class on the Management of Treatment-Experienced Patients

Now Available!

CME-Certified Video Module:

Strategies for Success in the Most Complex Cases: A Master Class on the Management of Treatment-Experienced Patients
In this video module, Program Director Kimberly Y. Smith, MD, MPH, and faculty members Daniel R. Kuritzkes, MD, and Andrew R. Zolopa, MD, review 2 challenging cases involving highly treatment–experienced multidrug-resistant patients. Challenge yourself to build the most appropriate new regimens for these patients.

CCO HIV Stay Tuned

Bimonthly CME-certified audio Podcasts, each supported by a variety of online resources.

Evolving Concepts in Antiretroviral Therapy—Volume 2, Edition 1 Watch and listen as W. David Hardy, MD, discusses the clinical relevance of select studies published the first quarter of 2009; Andrew R. Zolopa, MD, reports on the timing of antiretroviral initiation in patients presenting with an opportunistic infection; Anthony M. Mills, MD, discusses his approach to management and treatment of HIV-infected patients with cardiovascular risk; Scott L. Letendre, MD, challenges the participant to manage the treatment of a patient with neurocognitive decline; and Peter J. Ruane, MD, discusses the recently presented SWITCHMRK data on modifying a virologically suppressive antiretroviral regimen. Then download audio, video, and Capsule Summaries for additional reference. Click here to start.

HIV/AIDS Annual Update 2009

Clinical Care Options' HIV/AIDS Annual Update offers the latest information across a wide range of issues for the optimal clinical management of your patients. Expert faculty members prepared the following CME-certified educational modules that are now available on the CCO Web site:

Now Available!

CME-Certified Modules:

The Virus, the Tissues, and Immune Activation: What Makes HIV Infection Pathogenic?  Daniel C. Douek, MD, MRCP, PhD, reviews deletion of gut-associated lymphoid tissue in early HIV-1 infection and the implications for progression of HIV-associated disease.

New Insights Into Persistent Low-Level Viremia  Robert F. Siliciano, MD, PhD, reviews the contribution of viral dynamics and the inhibitory mechanisms of antiretroviral agents to the persistence of low-level HIV-1 viremia during HAART and proposes a quantitative approach to selecting optimal HIV-1 treatment regimens.

Timing and Choice of First-Line Antiretroviral Therapy  Joel E. Gallant, MD, MPH, reviews optimal strategies for the initial treatment of HIV-1 infection in the context of updated guideline recommendations and recent clinical trials data.

Inflammation and Non-AIDS Events: Are Antiretroviral-Treated Patients Aging Too Quickly and If So, Why?  Steven G. Deeks, MD, describes inflammation and immune activation related to HIV infection and how even though viral replication may be suppressed, HIV appears to mediate other disease states previously thought to be non-AIDS related.

Update on Managing Methamphetamine Abuse in the Setting of HIV Infection  Steven Shoptaw, PhD, offers practical management strategies for treating methamphetamine use in HIV-infected patients.

State-of-the-Art Management of Sexually Transmitted Diseases  Jeanne Marrazzo, MD, MPH, reviews current management strategies of sexually transmitted diseases in HIV-infected patients.

Biomedical Approaches to Prevention  Sharon L. Hillier, PhD, outlines the successes and failures of clinical trials of HIV prevention and describes current clinical trials of microbicides and antiretroviral therapy for pre-exposure prophylaxis.

Experiences as an HIV Provider in Africa  Charles Steinberg, MD, reviews data and personal experience about providing healthcare in the resource-poor nation Uganda in Africa.

HIV Journal Options - Volume 5, Issue 1

Stay up to date with the current medical literature through a CME-certified learning module and CCO’s Capsule Summaries of the most relevant published articles with accompanying Expert Commentaries and downloadable slidesets.

Topics Include:

• Raltegravir With Optimized Background Therapy for Resistant HIV-1 Infection
• Maraviroc for Previously Treated Patients With R5 HIV-1 Infection
• Week 48 Efficacy and Safety Results of the CASTLE Study
• Week 48 Efficacy and Safety Results of the ARTEMIS Study
• Use of NRTIs and Risk of Myocardial Infarction
• Long-term Consequences of Delayed Regimen Modification After Virologic Failure
• Antiretroviral Resistance and Clinical Progression
• Low CD4+ Cell Count and Atherosclerosis

The Evolving Management of Drug-Drug Interactions in HIV Infection

This new Treatment Update is designed to allow clinicians to explore clinically relevant drug-drug interactions.

Now Available!

CME-Certified Case Vignettes:

Management of a Patient Receiving an Initial Atazanavir/Ritonavir-Based Regimen With a Helicobacter Pylori Infection Ian McNicholl, PharmD, BCPS (AQ-Infectious Diseases), AAHIVE, describes the pharmacologic considerations of treating a Helicobacter pylori infection in an HIV-infected patient with dyslipidemia receiving an initial atazanavir/ritonavir-based regimen.

Considering Drug-Drug Interactions When Selecting a First-line Antiretroviral Therapy for a Patient With a Complex Medical History Charles W. Flexner, MD, and Paul Pham, PharmD, BCPS, coauthored this case vignette that describes the management of a patient with a medical history and multiple nonantiretroviral medications that increase the potential for drug-drug interactions.

Does Polypharmacy Increase the Likelihood of Renal Toxicity Among Persons With HIV? In this CME-certified Case Vignette, Lynda Szczech, MD, MSCE, FASN, discusses the management of an HIV–infected patient with diabetic nephropathy and heart failure who is being treated with multiple medications in addition to antiretrovirals.

Drug-Drug Interactions Tool This interactive tool will enable readers to select a specific antiretroviral agent from a listing of all FDA-approved antiretroviral agents and then either display and print a report of the interactions between this drug and other antiretroviral agents and commonly prescribed concomitant medications or select multiple concomitant agents from a listing of those most commonly used by HIV-infected patients and create a report on any interactions between the selected antiretroviral agents and other nonantiretroviral medications.

Answering the Questions: Initiating Antiretroviral Therapy

CCO’s expert faculty members provide answers to frequently asked questions regarding the initiation of antiretroviral therapy in this new Treatment Update. Discussions include key considerations on when to initiate therapy, assessing patients prior to treatment, and optimal initial regimen selection. Special populations of patients are addressed.

CME-Certified Modules:
Answering the Questions: Initial Antiretroviral Therapy
John A. Bartlett, MD; Paul E. Sax, MD; and Benjamin Young, MD, PhD, in this roundtable answer the questions most pertinent to the initiation of antiretroviral therapy. Special considerations for unique patients and situations are discussed.

Faculty Responses to Additional Questions on Initiating Antiretroviral Therapy 
John A. Bartlett, MD; Paul E. Sax, MD; and Benjamin E. Young, MD, PhD, answer the most compelling additional questions on initiating antiretroviral therapy in HIV-infected antiretroviral-naive patients.

Downloadable CCO Slideset:

• 2009 IAS Conference on HIV Pathogenesis, Treatment and Prevention
  
  
• 2009 Conference on Retroviruses and Opportunisitic Infections *
  
  
• 2008 International Congress on Drug Therapy in HIV Infection*
  
  
• 2008 ICAAC/IDSA Annual Meeting*
  
  

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

• European Guidelines for Use of Antiretroviral Therapy: Recent Changes and Emerging Data
  CCO’s expert faculty members review the most recent European guidelines on the frontline treatment of patients infected with HIV-1 and summarize new clinical findings that have led to changes in recommended treatment strategies and may impact future approaches to antiretroviral regimen selection.
  
  
• Answering the Questions: HIV Tropism in Clinical Practice 
  In each of these CME-certified modules, expert faculty members Eric S. Daar, MD; Joseph J. Eron, Jr., MD; and Jonathan M. Schapiro, MD, respond to frequently asked questions about HIV tropism, tropism testing, and the implications for clinical management of patients. An accompanying downloadable slideset provides a visual overview of the most pertinent data on HIV tropism.
  
  
• An Eye on the Future: Planning for Long-term Antiretroviral Success
  This new Treatment Update reviews critical aspects of first-line regimen selection as well as important antiretroviral management strategies in the context of potentially lifelong antiretroviral therapy.
   
  
• Evolving Options for First-line PI-Based Antiretroviral Regimens
  Through a CME-certified Interactive Virtual Presentation and downloadable slideset, this new Treatment Update delivers the latest information on key factors to consider when choosing among the different PI-based antiretroviral regimens available for the frontline treatment of HIV-1 infection.
  
  
• Assessing Antiretroviral Activity: A Practical Guide to Selecting New Agents for Treatment-Experienced Patients
  In this Treatment Update, CCO’s expert faculty members discuss the latest findings from clinical studies regarding the role of HIV resistance and tropism data in designing new regimens for treatment-experienced patients. Case Vignettes provide practical examples of clinical scenarios that may be encountered in practice.
  
  
• Toward Timely Treatment: Risks of and Strategies to Address Delayed Antiretroviral Therapy
  Through 2 CME-certified modules, CCO’s expert faculty members discuss key issues related to the timing of antiretroviral therapy initiation.
  
  
• Integrating New Antiretroviral Agents Into Therapeutic Strategies for Treatment-Experienced Patients
  Watch, listen, and make treatment decisions as Eric S. Daar, MD, leads you through a series of interactive clinical scenarios exploring the use of the newly approved antiretroviral agents in virologically suppressive regimens for treatment-experienced patients.
  
  
• The Role of Integrase Inhibitors in HIV Management
  Through a CME-certified video module and 3 downloadable slidesets, CCO’s expert faculty members explore key strategies for the effective use of integrase inhibitors in the context of the most recent clinical trials data and with consideration of mechanisms and consequences of resistance.
  
  
• CCO HIV Stay Tuned - Volume 1
  Bimonthly CME-certified audio Podcasts, each supported by a variety of online resources.

• Managing HIV-Infected Patients With Initial Regimen Failure
  This up-to-date Management Series provides an overview of the causes and consequences of treatment failure with first-line antiretroviral regimens as well as practical clinical strategies for avoiding and managing initial treatment failure in HIV-infected patients.
  
  
  

• Managing the Care of an HIV-Infected Patient With an Inaccurate Previous Treatment History
  Along with Peter J. Ruane, MD, choose management strategies for a challenging HIV-infected patient.
  
  
• Choosing an Optimal Second-Line Regimen for a Patient With Intermittent Adherence
  Join Karam Mounzer, MD, in managing the care of an HIV-infected patient with erratic behavior and intermittent adherence.
  
  
• A 30-Year-Old Female With Failure of an Initial PI-Based Regimen
  Join W. David Hardy, MD, in managing the care of an HIV-infected female with virologic failure of a first-line boosted PI-based regimen.
  
  

Quickly access answers to your point-of-care questions

LATEST UPDATES:

Hepatic Disease in HIV-Infected Patients: Updated to reflect recommendations in the December 2009 DHHS antiretroviral guidelines and November 2009 EACS guidelines. 

Primary Care for HIV-Infected Patients in Resource-Limited Settings: Updated to reflect November 2009 changes to WHO guidelines.

Topics

• Adverse Effects and Comorbidities
• Antiretroviral Management
• Epidemiology and Natural History
• Opportunistic Diseases and Coinfection
• Pharmacology
• Resistance
• Special Populations

Resources

• Advanced Search
• Animations
• Case Challenges
• Free Bookstore
• Live Events
• Slide Download Library
• Interactive Tools
• CCO inPractice

FEATURED VIDEO SEGMENT

A Must Read

Andrew R. Zolopa, MD, describes the clinical outcomes from the recently published ACTG A5164 study. Click here to start.

D:A:D Study: Increased Risk for MI Among HIV-Infected Patients With Exposure to Abacavir, Didanosine, Indinavir, or Lopinavir/Ritonavir

In this updated analysis, the D:A:D investigators present data on the association between 13 antiretroviral agents and cardiovascular risk.

Click here for related capsule summaries

Click here for more slides

Click here for more tools